Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
Identifieur interne : 000058 ( PubMed/Corpus ); précédent : 000057; suivant : 000059Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
Auteurs : Leo F. Buckley ; Judy W M. Cheng ; Akshay DesaiSource :
- Journal of cardiovascular pharmacology [ 1533-4023 ] ; 2020.
Abstract
Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.
DOI: 10.1097/FJC.0000000000000840
PubMed: 32301766
Links to Exploration step
pubmed:32301766Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.</title><author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author><author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author><author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name><affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32301766</idno><idno type="pmid">32301766</idno><idno type="doi">10.1097/FJC.0000000000000840</idno><idno type="wicri:Area/PubMed/Corpus">000058</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000058</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.</title><author><name sortKey="Buckley, Leo F" sort="Buckley, Leo F" uniqKey="Buckley L" first="Leo F" last="Buckley">Leo F. Buckley</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author><author><name sortKey="Cheng, Judy W M" sort="Cheng, Judy W M" uniqKey="Cheng J" first="Judy W M" last="Cheng">Judy W M. Cheng</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author><author><name sortKey="Desai, Akshay" sort="Desai, Akshay" uniqKey="Desai A" first="Akshay" last="Desai">Akshay Desai</name><affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of cardiovascular pharmacology</title><idno type="eISSN">1533-4023</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32301766</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4023</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of cardiovascular pharmacology</Title><ISOAbbreviation>J. Cardiovasc. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/FJC.0000000000000840</ELocationID><Abstract><AbstractText>Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Leo F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Judy W M</ForeName><Initials>JWM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Brigham and Women's Hospital.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy Practice, MCPHS University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Akshay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Brigham and Women's Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Pharmacol</MedlineTA><NlmUniqueID>7902492</NlmUniqueID><ISSNLinking>0160-2446</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32301766</ArticleId><ArticleId IdType="doi">10.1097/FJC.0000000000000840</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32301766
|texte= Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32301766" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |